Background and Purpose-Intracranial mechanical thrombectomy is a therapeutic option for acute ischemic stroke patients failing intravenous tissue plasminogen activator (IV tPA). We compared patients treated by mechanical embolus removal in cerebral ischemia (MERCI) thrombectomy after failed IV tPA with those treated with thrombectomy alone. Methods-We pooled MERCI and Multi MERCI study patients, grouped them either as failed IV tPA or non-IV tPA, and assessed revascularization rates, procedural complications, symptomatic hemorrhage rates, clinical outcomes, and mortality. We also evaluated outcomes stratified by the occlusion site and final revascularization. Results-Among 305 patients, 48 failed, and 257 were ineligible for IV tPA. Nonresponders to IV tPA trended toward a higher revascularization rate (73% versus 63%) and less mortality (27.7% versus 40.1%) and had similar rates of symptomatic hemorrhage and procedural complications. Favorable 90-day outcomes were similar in failed and non-IV tPA patients (38% versus 31%), with no difference according to occlusion site. Among patients failing IV tPA, good outcomes tended to occur more frequently in revascularized patients (47.1% versus 15.4%), although this relationship was attributable solely to middle cerebral artery and not internal carotid artery occlusions, with no difference in mortality. Among IV tPA-ineligible patients, revascularization correlated with good outcome (47.4% versus 4.4%) and less mortality (28.5% versus 59.6%). Conclusions-The risks of hemorrhage and procedure-related complications after mechanical thrombectomy do not differ with respect to previous IV tPA administration. Thrombectomy after IV tPA achieves similar rates of good outcomes, a tendency toward lower mortality, and similar revascularization rates when stratified by clot location. Good outcomes correlate with successful revascularization except with internal carotid artery occlusions in tPA-nonresponders. (Stroke. 2010;41:1185-1192.)
R evascularization rates in acute ischemic stroke patients with intravenous tissue plasminogen activator (IV tPA) treatment may be as low as 6% for internal carotid artery (ICA) terminus, 30% for middle cerebral artery (MCA) trunk, and 30% for basilar occlusions. 1, 2 Nonresponse to IV tPA is associated with poor clinical outcomes. 3 Although the initial IV tPA trials did not assess revascularization, 4 -6 failed IV tPA patients have emerged as a subgroup with persistent occlusions, confirmed by noninvasive or catheter angiography. [7] [8] [9] [10] The time window defining failed IV tPA has not been established. Because revascularization after IV tPA is typically confirmed by transcranial Doppler ultrasonography within the first hour, 11 this may be an appropriate window within which to consider rescue reperfusion therapies for IV tPA nonresponders.
The Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI trials were prospective, multicenter, endovascular mechanical thrombectomy trials for acute ischemic stroke patients treated within 8 hours of symptom onset who were either ineligible for or failed IV tPA therapy, introducing Merci Retriever thrombectomy as an option for acute ischemic stroke patients. [12] [13] [14] [15] The Multi MERCI trial also showed that significant hemorrhage from the combined use of IV tPA and thrombectomy (failed IV tPA group) was not significantly higher than with thrombectomy alone (non-IV tPA group). 14, 15 However, it is possible that the effect of nonresponse to IV tPA varies depending on occlusion location and final revascularization. We pooled data from these 2 trials and analyzed outcomes and revascularization rates in patients with failed IV tPA versus non-IV tPA, stratified by vessel occlusion.
Methods
Pooled data from the previously reported MERCI and Multi MERCI trials 13, 15 were analyzed retrospectively in this study. A family of Merci Retrievers (Concentric Medical, Inc.) was used to extract clot from intracranial vessels. The MERCI trial only enrolled patients who were ineligible for IV tPA. In Multi MERCI, patients receiving IV tPA (0.6 mg/kg or 0.9 mg/kg) within 3 hours of stroke onset were included if persistent vessel occlusion was confirmed by angiography. Intra-arterial (IA) tPA was only allowed in cases of thrombectomy failure after 6 passes or to treat distal embolus after successful proximal thrombectomy.
Patients were dichotomized into failed and non-IV tPA groups. Clinical variables, revascularization rates, symptomatic hemorrhage rates, clinical outcomes and mortality at 90 days, and clinically significant procedural complications were compared. Clot locations were confirmed by catheter angiography and were hierarchically categorized based on the most proximal occlusion location: ICA, MCA, or vertebro-basilar.
Successful revascularization was defined as achieving thrombolysis in myocardial infarction II or III flow in all treatable vessels (ICA, M1, M2, vertebral, and basilar) documented on final post-thrombectomy angiogram. CT or MRI brain imaging was performed at baseline, 24 hours, and at any time there was a decline in patient neurological status. Symptomatic intracranial hemorrhage was defined as a point increase of Ն4 in the National Institutes of Health Stroke Scale (NIHSS) score within 24 hours with evidence of any blood on 24-hour head CT/MRI scan or any intracranial hemorrhage in which no additional NIHSS scores were available followed by patient death. Intracerebral hemorrhages were further categorized as hemorrhagic infarction type I and II, or parenchymal hematoma types I and II, as described previously. 5 Procedure-related adverse events were adjudicated by an independent data safety monitoring board and were defined as vascular perforation, intramural arterial dissection, or embolization of a previously uninvolved territory, symptomatic hemorrhage, and access site complications requiring surgery or transfusion. Clinically significant procedural complications were defined as a procedure complication with decline in NIHSS score of Ն4 points or death, groin complication requiring surgery, or blood transfusion.
Neurological status was quantified by the NIHSS and modified Rankin Scale (mRS) at 90 days. Good outcome at 90 days was defined as mRS Յ2. Additional comparisons of revascularization, procedural complications, good outcomes, and mortality were stratified by the occlusion site, and outcomes were further stratified by final revascularization.
Categorical data were analyzed by the Fisher exact and 2 tests. Continuous data were assessed for normality by the KolmogorovSmirnov test; normally distributed continuous data were analyzed by Student t test, and for unevenly distributed continuous data, the Mann-Whitney U test was used. A P value Ͻ0.05 was considered statistically significant. No adjustment was made for multiplicity. Statistical analyses were performed using SAS software (version 8.2; SAS Institute Inc).
Results

Demographics
A total of 305 patients were enrolled in the 2 trials: 141 patients in MERCI and 164 patients in Multi MERCI.
Forty-eight (15.7%) failed IV tPA, and 257 (84.3%) were not eligible to receive IV tPA before mechanical thrombectomy. In the failed IV tPA group, the mean age was 67.8Ϯ12.7 years, and 56.3% (27 of 48) were women. Mean baseline NIHSS score was 19.1Ϯ5.5. The mean IV tPA dose was 57Ϯ16 mg. In the non-IV tPA group, the mean age was 67.6Ϯ16.3 years, and 51.4% (132 of 257) were women. Mean baseline NIHSS score was 19.8Ϯ6.7. Baseline characteristics (Table 1) for these 2 populations were similar with the exception of a higher distribution of comorbid dyslipidemia in those failing IV tPA (46.8% versus 31.6%; PϽ0.05).
Patients with failed IV tPA tended to have a shorter time to intervention and shorter procedure duration (4.0 versus 4.4 hours). Table 1 shows the distribution of occlusion locations, categorized hierarchically by the most proximal occlusion. The distribution of occlusion location was not different between groups, with the MCA being the most common, then the ICA, and then the vertebro-basilar system.
Revascularization Rates
The final revascularization rates were similar between groups (72.9% versus 63.0%), with comparable intergroup IA tPA use. In tPA-nonresponders, revascularization was achieved in 66.7% (12 of 18) of ICA, 74.1% (20 of 27) of MCA, and 100% (3 of 3) of vertebro-basilar occlusions (Table 2 ). In the non-IV tPA patients, revascularization was achieved in 61.7% (50 of 81), 61.6% (93 of 151), and 76.0% (19 of 25), respectively (Table 3 ). There was no intergroup difference.
Symptomatic Hemorrhage and Complications
Symptomatic hemorrhage was similar between groups (10.4% versus 8.6%). The 2.1% rate of symptomatic parenchymal hematoma II in patients with failed IV tPA was similar to the 1.9% rate in the non-IV tPA patients. Symptomatic hemorrhage rates by occlusion site were as follows for the failed and non-IV tPA groups, respectively: ICA, 11.1% for both; MCA, 11.1% versus 5.3%; and vertebrobasilar, 0% versus 20.0% (Tables 2 and 3 ). Symptomatic hemorrhage in ICA occlusions was similar between groups. Although all parenchymal hematoma II hemorrhages occurred with MCA occlusions in the failed IV tPA group, the rates of all symptomatic hemorrhages for both MCA and vertebro-basilar occlusions were similar to the non-IV tPA group.
Hemorrhage by Revascularization Status
In tPA-nonresponders, symptomatic hemorrhage occurred equally by revascularization status (8 
Procedural Adverse Events
Both groups had a similar rate of clinically significant procedural complications (4.2% versus 6.6%). In the failed IV tPA group, procedural complications only occurred with MCA occlusions, at a rate of 7.4%. In the non-IV tPA group, clinically significant complication rates by occlusion site were: ICA, 8.6%; MCA, 4.6%; and vertebro-basilar, 12.0%.
Clinical Outcomes
The rates of good clinical outcomes (mRS, 0 to 2) at 90 days were similar in the failed and non-IV tPA groups (38.3% versus 31.3%). Good outcomes by occlusion site in the failed and non-IV tPA groups were as follows, respectively (Tables  2 and 3 
Outcomes by Postprocedure Revascularization Status
In both groups, good clinical outcomes at 90 days occurred more frequently in subjects for whom revascularization was successful (Figure 1 ). In the failed IV tPA group, 47.1% (16 of 34) of revascularized patients had a good neurological outcome compared with 15.4% (2 of 13) of nonrevascularized patients (Pϭ0.09), powered by MCA (55% versus 0%) but not ICA occlusions (27% versus 33%). In the non-IV tPA group, 47.4% (72 of 152) of revascularized patients had a good neurological outcome compared with 4.4% (4 of 91) of nonrevascularized patients (PϽ0.001). When stratified by occlusion site, a positive relationship existed between revascularization and good outcome, with the exception of ICA occlusions failing IV tPA.
Across cohorts, revascularized patients had a similar rate of good outcomes in both groups (47.1% versus 47.4%), whereas nonrevascularized patients in the failed IV tPA group trended toward better outcome than nonrevascularized patients in the non-IV tPA group (15.4% versus 4.4%; Figure 2 shows 90-day good outcomes stratified by revascularization status, IV tPA status, and occlusion location.
Pϭ0.16).
Mortality
There was a trend toward less mortality at 90 days in the failed IV tPA group (27.7% [ 
Mortality by Postprocedure Revascularization Status
Nonrevascularized patients had higher rates of mortality in both the failed IV tPA and non-IV tPA groups (Figure 1 ). Revascularized and nonrevascularized patients in the failed IV tPA groups had similar mortality at 90 days (23.5% versus 38.5%). In contrast, the mortality in the revascularized non-IV tPA group (28.5%) was lower than those not revascularized (59.6%; PϽ0.001). Across cohorts, revascularized patients had a similar rate of mortality in both groups (23.5% versus 28.5%), although among nonrevascularized patients, there was trend toward decreased mortality in the failed IV tPA cohort (38.5% versus 59.6%; Pϭ0.23). Mortality results, stratified by revascularization status and site of vascular occlusion, are shown in Figure 3 .
Discussion
The combination of IV tPA followed by mechanical thrombectomy achieves similar rates of good outcomes compared with thrombectomy alone. Previous IV tPA use does not increase symptomatic hemorrhage risk or procedure-related complications after thrombectomy. Revascularization rates are similar between the failed and non-IV tPA groups when stratified by occlusion location. Revascularized patients have better outcomes regardless of occlusion site.
Results from 2 different IV thrombolysis studies showed that the ICA, MCA, and basilar artery occlusions respond differently to thrombolytics, and revascularization was more frequent in distal occlusions. 1, 2 Revascularization and good outcomes may be improved by a combined multimodal approach. 7-10,16 -21 In a series of 69 patients (50 MCA, 18 ICA, and 1 basilar occlusion) treated by IA thrombolysis after nonresponse to IV tPA, 9 the revascularization rate was 72.5%, similar to the 75% rate in another series of 16 patients with MCA and ICA occlusions. 8 Two studies also demonstrated improved revascularization with mechanical clot disruption after failed IV tPA. In 32 patients with persistent MCA or ICA occlusion after IA or IV Figure 1 . Ninety-day (90d) mRS by revascularization status in the cohort of failed IV tPA subjects (A; nϭ47) and the cohort that did not receive IV tPA (B; nϭ243). Brackets indicate the percentage of subjects achieving a good mRS score of 0 to 2. mRS scores of 3, 4 to 5, and 6 represent intermediate, poor neurological outcome, and death, respectively. 16 In 7 patients with basilar occlusions treated by combined IV tPA and mechanical thrombectomy (snares and suction devices) or IA tPA, 87.5% of patients were revascularized. 10 In our analysis, successful revascularization of ICA, MCA, and basilar artery occlusions was achieved with the Merci device in IV tPA nonresponders, with no difference in complications. Revascularization rates in our cohort of 66.7%, 74.1%, and 100% of ICA, MCA, and basilar occlusions, respectively, were comparable to those of previous combined approach cohorts.
We demonstrate no difference in the rates of symptomatic hemorrhage between patients either failing or ineligible for IV tPA who are subsequently treated with mechanical thrombectomy. The overall 10.4% rate of symptomatic hemorrhage in the combined IV tPA and thrombectomy group is comparable to the 8.2% rate from the pooled data of IV tPA trials. 22 Our observed rate is also lower than the 12.2% rate observed in IA thrombolysis and 20% rate in IA plus IV thrombolysis from one multicenter study 23 but slightly higher than the 6.2% and 5.8% rates from 2 other series of combined IA and IV thrombolysis. 8, 9 In our study, an 11.1% rate of symptomatic hemorrhage was found in patients with either ICA or MCA occlusions treated with a combined approach, whereas rates of symptomatic hemorrhage after thrombectomy alone were 11.1% in ICA, 5.3% in MCA, and 20% in basilar artery occlusions. Our rates of symptomatic hemorrhage in ICA occlusions in both groups were lower than the 18.8% rate seen in 16 patients treated with mechanical clot disruption after failed IV tPA. 16 Patients in our study also experienced parenchymal hematoma II hemorrhage less frequently than described in Inter- ventional Management of Stroke studies I and II, which occurred in 7.5% and 8.8% of patients, respectively. 24, 25 The decreased incidence of parenchymal hematoma II hemorrhages with the Merci device may be associated with the decreased use of thrombolytic drugs. Despite the theoretically increased risk of symptomatic hemorrhage with mechanical thrombectomy after failed IV tPA, there were numerically fewer procedure-related complications and mortality in the failed IV tPA group than the non-IV tPA group.
We found no difference in good outcomes and mortality between patients undergoing mechanical thrombectomy after failing or being ineligible for IV tPA. Similar rates of good outcomes have been reported in previous combined approach studies. 7-10,16 -21,25 In one study, 33 patients treated endovascularly (IA thrombolysis, Merci device, snare, or angioplasty) after IV tPA demonstrated lower mortality than 30 patients treated with IV tPA alone. 19 In our study, good outcomes and mortality rates were similar in patients with MCA, ICA, and basilar artery occlusions treated with the combined approach. In patients undergoing thrombectomy alone, the rates of good clinical outcomes were similar among the different sites of occlusion, but there was a trend toward lower mortality in patients with MCA occlusions than basilar or ICA occlusions. The only group in this entire cohort with no notable relationship between good outcome and revascularization was in tPA-nonresponders with ICA occlusions. The implications of this finding are unclear at this time, although they may be a result of an uneven distribution of pre-MERCI disability or higher hemorrhage transformation rates after revascularization in this subgroup.
Previous endovascular studies have shown a strong association between successful revascularization and favorable clinical outcomes, 13,15,26 -28 and our analysis supports this assertion. In the non-IV tPA group, revascularized patients had a higher proportion of good outcomes and a lower rate of mortality. In addition, patients with revascularized MCA or basilar occlusions had better outcomes and less mortality than the nonrevascularized patients in both treatment groups. With ICA occlusions, good outcome was more frequent in revascularized patients in the non-IV tPA group but not in the failed IV tPA group. This study has several limitations. Although the MERCI trial did not include failed IV tPA patients (by trial design), they contributed a greater number of non-IV tPA subjects for this analysis, facilitating a more meaningful comparison. Since the MERCI study, there has been progress in the Merci device, operator experience, and case selection, which may favor the failed IV tPA group (all from Multi MERCI). In addition, the failed IV tPA group presented earlier than the non IV tPA group, and since time from symptom onset to tPA bolus has also been shown to affect outcomes in the IV tPA trials, this may have contributed to detected differences.
In conclusion, the risk of symptomatic hemorrhage and procedural complication using the Merci Retriever after failed IV tPA is the same as using thrombectomy alone. Thrombectomy after IV tPA achieves similar rates of good outcomes, a tendency toward lower mortality, and similar revascularization rates when stratified by clot location. Good outcomes correlate with successful revascularization except with ICA occlusions in tPA-nonresponders. [9, 11] 。 与先 前 的 MERCI 和多 中 心 MERCI 试验分析相比，经机械取栓术治疗后的 MCA M1 组 60% 的血管再通率与 ICA 闭塞组 63% 的血管再通率相似，低于椎基底动脉闭塞组 78% 的 血管再通率 [17, 18] [9, 10] 。根据经颅多普 勒超声标准，MCA M2 与 M1 闭塞患者接受 IV tPA 治疗后，2 小时的完全再通率分别为 44.2%(50/113) 和 30%(49/163) [9] 。另一项采用 CT 血管造影和 / 或 经颅多普勒超声监测的研究，IV tPA 24 小时后 53% 
Appendix 1 MERCI Trial Investigators
颅内大动脉闭塞引起的急性缺血性卒中患者对 溶栓治疗的反应不尽相同，可能取决于动脉闭塞的 位置不同。在美国神经疾病与卒中研究所、欧洲急 性卒中协作研究 (ECASS) 以及阿替普酶静脉注射 (IV) 非介入治疗急性缺血性卒中的临床试验中，使 用组织型纤溶酶原激活剂 (tPA) 静脉溶栓，由于缺乏 对血栓的准确定位，动脉闭塞类型既不影响血管再 通状态也不影响临床结局 [1-4] 。大脑中动脉 (MCA) 供血区的卒中在缺血性卒中的所占比例最大。然而， IV 和动脉内 (IA) 溶栓治疗则很少报道血管再通状态 和临床结局在 MCA 主干 (M1) 闭塞和单独第二段 (M2) 闭塞中的差别 [1-8] 。最近应用经颅多普勒超声和 / 或 CT 血管成像的研究发现在 IV tPA 治疗后，MCA M2 闭塞的血管再通状态优于 MCA M1 闭塞 [9,10] 。 具有 良好临床结局的 MCA M2 闭塞患者约两倍于 MCA M1 闭塞患者 [9] 。 急性脑血栓栓塞溶栓试验Ⅱ (PROACT II) 研究 纳入的 MCA M1 闭塞患者占患者总数的 61.7%，其 余 大 多 是 单 独 MCA M2 闭 塞 ；然 而， 根 据 M1 与 M2 闭塞分层比较临床结局的研究罕有报告 [5] 。 最近 的尿激酶 IA 溶栓治疗的研究显示 MCA M1 闭塞的 血管再通状态要优于单独 M2 闭塞，但却没有描述 不同闭塞部位与临床结局的关系 [11,12] 。 对于起病 8 小时内 IV tPA 治疗不适用或失败的 急性缺血性卒中患者，应用 Merci 器械进行机械取 栓是一种很有前景的替代疗法 [13-17] 。脑缺血机械取 栓 (MERCI) 和多中心 MERCI 第一部分试验的汇总 分析已经证明，颈内动脉闭塞的患者可以达到相对 较高的血管再通率 [17] 。 然而，它并没有评估 MCA M2 闭 塞 与 MCA M1 闭 塞 的 机 械 性 血 管 再 通 的 结 局差异。本研究的目的是评价经过血管造影确定的 MCA M1 闭塞与单独 M2 闭塞的急性缺血性卒中患 者使用 Merci Retriever 装置进行机械取栓术是否会 影响其血管再通状态。同时本研究也旨在通过血管 再通状态比较不同组 (M1 vs. M2) 中所有 MCA 闭塞 患者使用机械取栓术的安全性和有效性。 方法 MERCI 与多中心 MERCI 试验的汇总数据对确 定的急性 MCA 卒中进行了回顾分析。汇总数据包 括总共 305 例缺血性卒中患者，其中 141 例来自于 MERCI 试 验，164 例 来 自 于 多 中 心 MERCI 试 验。 这两个试验的详细计划书在之前的研究中已经作了 描述 [13-17] 。简单来说，纳入试验的患者不是不适合 进行 IV tPA 治疗，就是经过导管法血管造影确认接 受 IV tPA 治疗后闭塞的血管未再通。试验使用一类 X 系 列 和 L5 Merci Retriever 装 置 (Concentric Medi- cal, Inc, Mountain View, Calif) 从管腔取出血栓试图 来使闭塞的颅内血管再通。第一代装置 (X4、X5 和 X6 Retriever) 在两个试验中都有应用，而第二代装 置 (L5 Retriever 装置 ) 只用在多中心 MERCI 试验中。 IA tPA 被允许在治疗中装置 6 次疏通依然失败或成 功施行近端血栓去除术后，溶解装置无法靠近的远 端血栓时应用。两个研究方案中，任何部位的闭塞 都不允许使用血管成形术或支架。 本研究纳入经数字减影血管造影确定的单独 MCA M1 和 / 或 M2 闭塞的患者。分析中排除了那 些 ICA/MCA 串联闭塞或 ICA-T 闭塞的患者。患者 分为 MCA M1 闭塞组和单独 MCA M2 闭塞组。成功 的血管再通定义为经数字减影血管造影所确认的所 有应治疗的血管经治疗后达到心肌梗塞溶栓 (TIMI) 血流分级的 II 级或 III 级。CT 或 MRI 扫描在基线、 24 小时以及患者神经状态下降的任何时间进行。根 据 ECASS 试验的分类，大脑内出血分为出血性梗 死 I 和 II 型或脑实质血肿 I 和 II 型。症状性出血是 指 24 小 时 内 NIHSS 分 数 增 加 ≧ 4 分， 且 24 小 时 内头部 CT/MRI 扫描发现有出血的证据，或在除和 之外无更多合适的 NIHSS 分数比基线线时没变化， 但患者死亡有的任何颅内出血。操作相关的不良事 件由独立的数据安全与监督委员会裁定，且被定义 为血管穿孔、动脉壁内夹层、或之前未受累区域栓 塞、症状性出血，以及需要外科手术或输血处理的 操作区并发症。临床上操作相关的严重并发症是指 NIHSS 降低≧ 4 分的操作并发症或死亡、需要外科 手术或输血处理的腹股沟区并发症。 神经状态由 NIHSS 和 30 及 90 天的改良 Rankin 评分 (mRS) 来评定。各闭塞组患者的评估内容包括血 管再通率、出血转化率、临床上严重的操作相关并发 症、90 天临床结局及死亡率。90 天良好的结局被定义 为 mRS ≤ 2。由于单独 M2 闭塞样本较小，M1 和 M2 闭塞的数据被汇总起来并进行多元 logistic 回归分析 以此来确定 90 天良好结局的独立预测变量。对血管 再通状态分层后进行临床特点、 并发症和结局的比较。 组与组之间差异的比较采用 95% CI。如果这 个区间不包含 0，组之间的差异在 P=0.05 时被认为 是有意义的。虽然这是一个回顾性的亚组分析，但 所考虑的两个组的样本大小应该是在两组间结局比 较上至少具有 80% 的效能检出 28% 的绝对差异和 50% 的效能检出 20% 的绝对差异。单因素分析确定 90 天的良好结局的独立预测变量，其中所有 Wald χ 2 P<0.2 变量都将纳入多元 logistic 回归模型去确定 90 天良好结局的预测变量。该模型按前进 / 后退逐 步回归的方法来建立，且基于 χ 2 的统计值，变量为 0.05 时进入模型而在 0.10 时离开该模型。在主要效 用的模型建立后，任何有意义的双向交互条件存在 的假设使用似然比 χ 2 (G2) 统计进行检测。最终的模 型由 Hosmer 和 Lemeshow 检验进行拟合度的检测。 P<0.05 认为有统计学意义。本文中的统计分析是使 用 SAS 软件来完成的。(8.2 版本 ；SAS 公司 ) 结果 MCA卒中患者的人口学特征 在 MERCI 和 多 中 心 MERCI 试 验 中， 对 178 例 经 血 管 造 影 确 定 为 MCA 闭 塞 的 患 者 进 行 了 治 疗。 其 中 80 例 患 者 来 自 MERCI 试 验，98 例 来 自 多 中 心 MERCI 试 验。 平 均 年 龄 69.0 岁 (SD 15.7)， 103(57.9%) 为 女 性 患 者。 平 均 基 线 NIHSS 分 数 是 18.8 分 (SD 5.8)， 范 围 为 9 至 40 分。 队 列 中 27(15.2%) 例患者接受了 IV tPA 治疗并在进行机械 取栓前均未再通 ；剩余的 151 例患者则不适合接受 IV tPA 治疗。患者从卒中起病至器械进入动脉的平 均时间为 4.3 小时 (SD 1.6)，范围为 0.7 至 10.8 小时。 178 例患者中，84.3%(n=150) 表现为单独 MCA M1 闭 塞 或 M1/M2 合 并 的 闭 塞，15.7%(n=28) 表 现 为 单 独 MCA M2 闭 塞。 在 150 例 MCA M1 闭 塞 患 者 中，73 例 来 自 MERCI 试 验，77 例 来 自 多 中 心 MERCI 试验。在 28 例 MCA M2 闭塞患者中，7 例 来自 MERCI 试验，21 例来自多中心 MERCI 试验。 各组患者的基线特征 ( 年龄、性别、NIHSS 分数、 起病至进入动脉的时间以及联合 tPA 的使用 ) 均没 有统计学差异。MCA M1 闭塞患者可能更易患冠状 动脉病，且凝血酶原时间更短，收缩压更低 ( 表 1)。 在 M1 组中，最常使用 X6 和 L5 装置 ( 均为 44.7%)， X5(34.0%) 和 X4(6.7%) 的使用则较少。在 M2 组中， 最常用的是 L5 装置 (53.6%)，紧接着是 X6(28.6%)， 之后是 X5(25.0%)，未使用 X4。两组中，7% 的患 者在评定其基线 NIHSS 分数时应用了镇静剂。尽管 与 M1 组 (52.5%) 相比，M2 组 (73.1%) 患者存在明 显更高比例的严重或完全性失语，但两组中 NIHSS 的运动评分部分无统计学差异。 血管再通率 经 Merci 治疗后的即时血管再通率 (TIMI II/III 血 流 分 级 ) 在 MCA M1 组 与 单 独 M2 组 中 分 别 为 46.0% 和 71.4%( 表 2)。包括接受联合治疗的患者在 内，单独 MCA M2 组的最终血管再通率高于 MCA M1 组 (。而单独 MCA M2 闭塞 82% 的血管 再通率则明显高于其他位置的闭塞。 本研究中机械取栓治疗 MCA 闭塞后，63.5% 的 血管再通率高于其他试验中只用 IV 溶栓治疗的患 者。有研究报告，起病 6 小时内 18% 的 MCA 心源 性栓塞患者可出现由经颅多普勒超声确定的自发再 通 [19] 。在 PROACT II 研究中，卒中起病后 6 到 8 小 时，大约 18% 的接受静脉肝素治疗后的急性 MCA 闭塞安慰剂组患者，可发生经血管造影确定的自发 再通 [5] 。 另一项基于 82 例 MCA 主干闭塞患者的研究， 采用 TIMI 血流分级和 MR 血管造影确定自发血管再 通，其结果显示起病后 24 小时，IV 溶栓组比未溶 栓组具有更高的自发血管再通率 [20] 。IV 溶栓组和未 溶栓组的局部和全部血管再通率 (TIMI II 级和 III 级 ) 分别为 38.5% 和 24% [20] 。 尽管在已发表的 IV 溶栓试验数据中，MCA M1 与单独 M2 闭塞的血管再通状态差异未予报道，但 本研究中单独 MCA M2 闭塞的血管再通优于 M1 闭 塞，与最近两篇 IV 溶栓研究一致的 M1 闭塞患者 (n=32) 和 68% 的 M2 闭塞患者 (n=19) 达到完全再通 [10] 。 对 IV tPA 后进行取栓治疗与只 进行取栓治疗的血管再通率比较超出了我们目前研 究的范围。取栓前的 IV tPA 治疗会软化凝块，促进 Merci 装置穿透凝块和取回。对不同位置动脉闭塞采 用 IV tPA 后再行机械取栓治疗，这种疗法产生的潜 在血管再通的益处应在以后的研究中进行探讨。 与 PROACT II 研 究 中 接 受 治 疗 的 121 例 患 者 相比，本研究的中位基线 NIHSS 和平均年龄均高 于 PROACT II( 基 线 NIHSS ：18 vs. 17 ；年 龄 ：69 岁 vs. 64 岁 )，但本组患者与其有相似的血管再通 率 (MERCI/ 多 中 心
